EGFR and ovarian carcinoma: Immunostaining for EGFR was positive in 32% (10/31) of samples comprising of 1 breast carcinomas, 5 colon carcinomas, 1 ovarian carcinoma, 1 sarcoma, 1 skin melanoma and 1 carcinoma of unknown primary site.